Currently Viewing:
The American Journal of Managed Care June 2012
Thromboembolism Prophylaxis in Medical Inpatients: Effect on Outcomes and Costs
Onur Baser, MS, PhD; Nishan Sengupta, PhD; Anne Dysinger, MA; and Li Wang, MA, PhD
Racial Disparities in Lipid Control in Patients With Diabetes
Darcy Saffar, MPH; L. Keoki Williams, MD, MPH; Jennifer Elston Lafata, PhD; George Divine, PhD; and Manel Pladevall, MD, MS
Automating Care Quality Measurement With Health Information Technology
Brian Hazlehurst, PhD; Mary Ann McBurnie, PhD; Richard A. Mularski, MD, MSHS, MCR; Jon E. Puro, MPA-HA; and Susan L. Chauvie, RN, MPA-HA
Currently Reading
Role of Insurance, Income, and Affordability in Human Papillomavirus Vaccination
Nadereh Pourat, PhD; and Jenna M. Jones, MPH
Quality Care Opportunities: Refining Physician Performance Measurement in Ambulatory Care
Kimberly M. Lovett, MD; and Bryan A. Liang, MD, PhD, JD
Unintended Consequences of a Quality Measure for Acute Bronchitis
Serena Roth, MD; Ralph Gonzales, MD, MSPH; Tammy Harding-Anderer, PhD; Frederick J. Bloom, Jr, MD, MMM; Thomas Graf, MD; Melissa S. Stahl, MPH; Judith H. Maselli, MSPH; and Joshua P. Metlay, MD, PhD
Impact of Positive Airway Pressure Among Obstructive Sleep Apnea Patients
Qian Cai, MS, MSPH; Hiangkiat Tan, MS, BPharm; and Joseph Singer, MD
Barriers to Transition of Obese Patients From Hospital to Community
Jane Miles, MSN, RN, NEA-BC; Darren P. Anderson, MSN, RN, ACM; Martha Engelke, PhD; Mary K. Kirkpatrick, RN, MSN, EdD; Mary Lisa Pories, MSW; Wanda G. Waters, RN, BSN; Frank R. Watkins, RN, CCRC; Marie E. Pokorny, RN, MSN, PhD; and Mary Ann Rose, MSN, EdD

Role of Insurance, Income, and Affordability in Human Papillomavirus Vaccination

Nadereh Pourat, PhD; and Jenna M. Jones, MPH
Compared with insured adults, uninsured adults in California had less knowledge of the human papillomavirus vaccine and were less likely to be vaccinated.
Other studies have also found racial/ethnic differences in interest in vaccination,27-30 and our findings may reflect unmeasured factors such as social/cultural responses to professional recommendations or vaccine availability at usual source of care.31 Intentions were found to correlate highly with actual vaccination among Latino and African American parents.32 The higher likelihood of vaccine initiation among Latino parents may reflect the impact of targeted vaccination programs in some communities.6,32

Improvement in HPV vaccination rates among eligible populations (eg, older age eligible women, college-educated individuals, young daughters of married parents) is most effectively accomplished by addressing differences among these groups in knowledge of the vaccine, completion of the series, and initiating the vaccine at an early age.33,34 Successful outreach should also emphasize the importance of vaccination despite religious or moral beliefs surrounding sexual activity among young females, alleviating skepticism about the effectiveness of the vaccine,33,34 changing normative beliefs about the society’s approval of the decision to vaccinate,12 and framing the importance of vaccination to different populations.35

The positive relationship of receipt of a flu shot to parental HPV knowledge, vaccine initiation by adults and parents, and interest in HPV vaccination may indicate better effectiveness of advertising or educational campaigns among those who are prevention oriented and have a higher propensity for preventive care. The state-by-state variations in population and healthcare system characteristics indicates that policy solutions to improve HPV vaccination should vary. For example, the racial/ethnic diversity of the California population indicates the need for multiple tailored and culturally competent outreach strategies that are not needed in states with lower diversity. Mandatory HPV vaccination is another strategy to increase vaccination rates and is proposed in 41 states; Virginia and District of Columbia have enacted this law.36 However, public education campaigns to instill the prevention orientation are still needed and could be further reinforced in current attempts to increase delivery of preventive and primary care under the medical home model. Also, efforts to improve HPV vaccination rates should focus on barriers not examined here, such as restrictions in availability of the vaccine in clinical settings and consent law requirements.

Author Affiliations: From University of California Los Angeles Center for Health Policy Research (NP), Department of Health Services (NP, JMJ), University of California Los Angeles, Los Angeles, CA.


Funding Source: None.


Author Disclosures: The authors (NP, JMJ) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.


Authorship Information: Concept and design (NP); acquisition of data (NP, JMJ); analysis and interpretation of data (NP, JMJ); drafting of the manuscript (NP, JMJ); critical revision of the manuscript for important intellectual content (NP, JMJ); statistical analysis (NP, JMJ); provision of study materials or patients (NP); obtaining funding (NP); administrative, technical, or logistic support (NP); and supervision (NP).


Address correspondence to: Nadereh Pourat, PhD, UCLA Center for Health Policy Research, 10960 Wilshire Blvd, Ste 1550, Los Angeles, CA 90024. E-mail: pourat@ucla.edu.
1. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244-251.


2. Spurgeon SA, Johnston D, Pefole M, Fleishman V. Challenges in Vaccine Policy: A Case Study of the HPV Vaccine. Cambridge, MA: New England Healthcare Institute; August 2006. www.nehi.net/uploads/full.../hpv_report_final_color_8.29.06.pdf. Accessed April 19, 2012.


3. The Henry J. Kaiser Family Foundation. California: cervical cancer incidence rate per 100,000 women by race/ethnicity, 2007. http://www.statehealthfacts.or/profileind.jsp?ind=474&cat=10&rgn=6. Accessed September 20, 2011.


4. The Henry J. Kaiser Family Foundation. HPV Vaccine: Implementation and Financing Policy in the U.S. Washington, DC: The Henry J. Kaiser Family Foundation; 2008.


5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102(5A)(suppl):3-8.


6. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.


7. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8):821-832.


8. Stanley M. Introduction: the human papillomavirus VLP vaccines. Gynecol Oncol. 2010;118(1)(suppl 1):S1.


9. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 2009;84(10):864-870.


10. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115(3)(suppl):S15-S23.


11. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5):1415-1423.


12. California Health Benefits Review Program. A Report to the 2007-2008 California State Legislature: Analysis of Assembly Bill 1429: Human Papillomavirus Vaccination. Oakland, CA: California Health Benefits Review Program; 2007.


13. Vetter KM, Geller SE. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer. J Womens Health (Larchmt). 2007;16(9):1258-1268.


14. National Conference of State Legislatures. HPV vaccine. http://www.ncsl.org/default.aspx?tabid=14381. Updated March 2010. Accessed September 1, 2010.


15. Conroy K, Rosenthal SL, Zimet GD, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt). 2009;18(10):1679-1686.


16. Dempsey AF, Davis MM. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care. 2006;12(17)(suppl):S484-S491.


17. California Health Interview Survey. CHIS 2005 Methodology Series. Report One. Sample Design. http://www.chis.ucla.edu/pdf/CHIS2005_method1.pdf. Published April 2007. Accessed April 15, 2008.


18. Andersen RM, Davidson PL. Improving access to care in America: individual and contextual indicators. In: Andersen RM, Rice TH, Kominski GF, eds. Changing the U.S. Health Care System. 3rd ed. San Francisco, CA: Jossey Bass; 2007.


19. Anhang Price R, Tiro JA, Saraiya M, Meissner H, Breen N. Use of human papillomavirus vaccines among young adult women in the United States: an analysis of the 2008 National Health Interview Survey. Cancer. 2011;117(24):5560-5568.


20. Wong CA, Berkowitz Z, Dorell CG, Anhang Price R, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9- to17-year-old girls: National Health Interview Survey, 2008. Cancer. 2011;117(24):5612-5620.


21. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey—Adult 2007. Prev Med. 2009;48(5):426-431.


22. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2009. MMWR Morb Mortal Wkly Rep.2010;59(32):1018-1023.


23. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Morb Mortal Wkly Rep. 2010;59(36):1184]. MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629.


24. Mast EE, Margolis HS, Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part I: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-23.


25. Mast EE, Weinbaum CM, Fiore AE; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults [published correction appears in MMWR Morb Mortal Wkly Rep. 2007;56(42):1114]. MMWR Recomm Rep. 2006;55(RR-16):1-33.


26. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination—United States, 1982-2002. MMWR Morb Mortal Wkly Rep. 2002;51(25):549-552, 563.


27. Yeganeh N, Curtis D, Kuo A. Factors influencing HPV vaccination status in a Latino population; and parental attitudes towards vaccine mandates. Vaccine. 2010;28(25):4186-4191.


28. Read DS, Joseph MA, Polishchuk V, Suss AL. Attitudes and perceptions of the HPV vaccine in Caribbean and African-American adolescent girls and their parents. J Pediatr Adolesc Gynecol. 2010;23(4):242-245.


29. Bastani R, Glenn BA, Tsui J, et al. Understanding suboptimal HPV vaccine uptake among ethnic minority girls. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1463-1472.


30. Gerend MA, Magloire ZF. Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults. J Adolesc Health. 2008;42(3):237-242.


31. Bynum SA, Brandt HM, Sharpe PA, Williams MS, Kerr JC. Working to close the gap: identifying predictors of HPV vaccine uptake among young African American women. J Health Care Poor Underserved. 2011;22(2):549-561.


32. Perkins RB, Pierre-Joseph N, Marquez C, Iloka S, Clark JA. Why do low-income minority parents choose human papillomavirus vaccination for their daughters? J Pediatr. 2010;157(4):617-622.


33. Daley EM, Vamos CA, Buhi ER, et al. Influences on human papillomavirus vaccination status among female college students. J Womens Health (Larchmt). 2010;19(10):1885-1891.


34. Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD. Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Women’s Health.10(1):27.


35. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstetrics Gynecol. 2008;111(5):1103-1110.


36. Gostin LO. Mandatory HPV vaccination and political debate. JAMA. 2011;306(15):1699-1700.
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up